Bicara Therapeutics Reports Q3 GAAP EPS Miss Amid Increasing Cash Reserves
Bicara Therapeutics (BCAX) reported third-quarter GAAP earnings per share (EPS) of -$1.04, missing analyst expectations by $0.22. The loss reflects the ongoing costs associated with the company's clinical development stage. Despite the earnings miss, the company demonstrated growth in its liquidity position. As of September 30, 2026, Bicara held $442.3 million in cash, cash equivalents, and marketable securities, an increase from the $414.8 million reported at the end of the previous period.
Tickers: $BCAX
Topics: cash position earnings miss GAAP EPS